更新于：2024-12-12
Lactulose
乳果糖
更新于：2024-12-12
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 荷兰 (1964-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C12H22O11 |
InChIKeyPFCRQPBOOFTZGQ-VZXVHDRGSA-N |
CAS号4618-18-2 |
关联
111
项与 乳果糖 相关的临床试验Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE): an Invesitgator-initiated, Open-label, Multicenter, Randomized Controlled Trial
A Randomized, Multicenter, Open Label, Two Arm, Prospective, Parallel Study to Evaluate the Impact of Addition of Synbiotic Combination to Lactulose in Management of Functional Constipation. - NIL
Branch Chain Amino Acids vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of Hepatic Encephalopathy: Double-blind Placebo-controlled Multicentric Randomized Controlled Trial
100 项与 乳果糖 相关的临床结果
登录后查看更多信息
100 项与 乳果糖 相关的转化医学
登录后查看更多信息
100 项与 乳果糖 相关的专利（医药）
登录后查看更多信息
2,890
项与 乳果糖 相关的文献（医药）2024-12-01AMERICAN JOURNAL OF CLINICAL NUTRITION
A cross-sectional study of associations between the 13C-sucrose breath test, the lactulose rhamnose assay, and growth in children at high risk of environmental enteropathy
Article
作者: Devi, Sarita ; Huq, Sayeeda ; Yazbeck, Roger ; Owino, Victor O ; Brouwer, Andrew F ; Konyole, Silvenus Ochieng ; Lee, Gwenyth O. ; Owino, Victor O. ; Paredes-Olortegui, Maribel ; Morrison, Douglas J ; Kelly, Paul ; Brouwer, Andrew F. ; Kosek, Margaret N. ; Morrison, Douglas J. ; Kosek, Margaret N ; Lee, Gwenyth O ; Shivakumar, Nirupama
BACKGROUND:
Environmental enteropathy' (EE) is common among children who are highly exposed to enteric pathogens in low-resource settings. We optimized and validated a stable isotope-based breath test of intestinal sucrase activity (13C-SBT) as a noninvasive test of carbohydrate digestion and metabolism.
OBJECTIVES:
The primary objective of this study was to assess the relationship between the 13C-SBT and the lactulose/rhamnose ratio (LR) and growth in children. Secondary objectives were to assess the relationship between the 13C-SBT and additional biomarkers of EE. We also characterized the relationship between the 13C-SBT and child sex and dietary diversity, as well as household socio-economic status and food security.
METHODS:
In this cross-sectional study, 12-to-15-mo-old children were recruited in Bangladesh, India, Kenya, and Peru. Children were assessed with a 4-h 13C-SBT and a 90-min LR test. Plasma was collected to determine the citrulline and kynurenine/tryptophan ratio. Length and weight were measured, and other variables were assessed through questionnaires. For a subset of children, anthropometry was re-measured after 3 mo. Linear regression was used to examine associations corresponding to each objective.
RESULTS:
Three sites generated 13C-SBT breath curves that enabled pooled analysis. Differences in 13C-SBT breath curves, LR ratios, and other EE biomarkers were observed between sites. No associations were observed for 13C-SBT summary measures and LR or child growth [e.g., the association between LR and cumulative percent dose recovered at 90 min: -0.39; 95% confidence interval (CI): -1.79, 0.70]. Length-for-age and weight-for-age were positively associated with the time to 50% of dose recovered (0.05; 95% CI: 0.01, 0.09, and 0.05; 95% CI: 0.02, 0.07, respectively), and dietary diversity was associated with time at which 50% of the dose recovered by 240 min is recovered and cumulative percent dose recovered at 90 min (-0.10; 95% CI: -0.18, -0.02 and 2.67; 95% CI: 0.47, 4.88, respectively).
CONCLUSIONS:
In children at risk of EE, there were no associations between the 13C-SBT, LR, or other EE biomarkers encompassing different pathophysiological domains of EE. This trial was registered at clinicaltrials.gov as NCT04109352.
2024-12-01Annals of Hepatology
The burden of hepatic encephalopathy and the use of albumin as a potential treatment
Review
作者: Caraceni, Paolo ; Pompili, Enrico ; Bajaj, Jasmohan S
As a potential sequela of cirrhosis, hepatic encephalopathy (HE) significantly impacts the lives of patients and caregivers and places a substantial burden on the healthcare system. With an increasing incidence over time and a cumulative effect on cognition, HE adversely effects quality of life, morbidity and mortality in patients with cirrhosis. HE can range from minimal or covert (MHE/CHE) to overt and symptomatic (OHE). HE has profound impacts on the health and wellbeing of patients and their families and caregivers. Effective treatments could improve the quality of life for all those affected. In this article, we discuss the existing treatments for HE and focus on the potential role of albumin in the treatment of HE. Currently approved therapies for HE (lactulose and rifaximin) are focused on decreasing the formation of ammonia in the gastrointestinal tract. Among the many agents with alternative mechanisms being investigated for treatment of HE, albumin has been studied in clinical trials with acute (≤ 3 days), short-term (up to 2 weeks) prolonged (> 2 weeks) and long-term administration (months). Current studies indicate that acute or short-term administration of albumin does not provide significant benefit for patients with OHE. However, there is increasing evidence that prolonged or long-term albumin therapy can help improve cognition in OHE and prevent recurrence. Additional studies are needed to substantiate these positive findings for longer term administration of albumin in HE and to increase our comprehension of the pharmacologic basis of the effects of albumin.
2024-11-30Clinical Endoscopy
Novel regimen for colonoscopy bowel preparation with oral lactulose: a prospective comparative study
Article
作者: Arantes, Vitor N ; Carvalho, Danilo ; Ramos, Josué Aliaga
Background/Aims: Polyethylene glycol (PEG) is considered the gold standard regimen for bowel preparation; however, due to the necessity of a large volume, patient tolerance is impaired. Therefore, lactulose is a novel alternative for colonoscopy preparation. This study aimed to investigate the efficacy and safety of lactulose-based bowel preparations in comparison with PEG for colonoscopy.Methods: This is a prospective, non-blinded, comparative study. Outpatients were randomly divided into two groups: group 1 (111 patients), PEG; and group 2 (111 patients), lactulose. The following clinical outcomes were assessed in each group: degree of bowel clearance using the Boston bowel preparation score, colorectal polyp detection rate, adenoma detection rate, tolerability, and side effects.Results: The rate of inadequate bowel preparation was 8.1% and 1.8% for the PEG and lactulose groups, respectively (p=0.030). The Boston bowel preparation score for the entire colon was 7.34±1.17 and 8.36±1.09 for the PEG and lactulose groups, respectively (p<0.001). The satisfactory overall experience rates were 27.9% and 62.2% for the PEG and lactulose groups, respectively (p<0.001).Conclusions: The novel bowel preparation with oral lactulose was superior to that with PEG in terms of colon cleansing, adenoma detection rate, tolerance, and patient experience.
100 项与 乳果糖 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高氨血症 | 日本 | 2018-09-21 | |
| 慢性便秘 | 澳大利亚 | 2014-02-13 | |
| 肝性脑病 | 澳大利亚 | 2014-02-13 | |
| 便秘 | 荷兰 | - | 1964-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结肠疾病 | 临床2期 | 美国 | 2014-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 56 | (Lactulose) | 膚艱網鑰夢獵廠築範觸(窪鹽築願壓鏇觸積夢構) = 餘憲簾糧繭淵壓憲夢鹹 積淵衊選醖鏇鑰範選膚 (齋襯夢繭範鹽繭齋窪壓, 鹽憲鑰顧構範廠網餘顧 ~ 範膚鏇鏇鑰餘鹹顧糧膚) 更多 | - | 2023-11-21 | ||
placebo (No Treatment) | 膚艱網鑰夢獵廠築範觸(窪鹽築願壓鏇觸積夢構) = 構鬱衊襯積觸衊顧積醖 積淵衊選醖鏇鑰範選膚 (齋襯夢繭範鹽繭齋窪壓, 憲廠鬱範觸膚廠夢鹹範 ~ 齋繭製鏇願鬱窪觸積窪) 更多 | ||||||
临床4期 | - | 膚憲簾窪範遞鑰衊鏇築(製鏇夢廠積蓋選夢簾艱) = 窪築憲蓋積鏇簾衊夢繭 壓膚襯鹽鏇構夢醖餘鬱 (顧鏇糧壓築築願構醖積 ) | 积极 | 2023-01-01 | |||
N/A | - | - | - | 2022-06-24 | |||
临床4期 | 222 | (Rifaximin 550 mg BID) | 廠淵淵製襯願範網顧壓(鑰襯廠窪淵鹽積壓襯憲) = 餘鹽顧淵憲鹽獵鑰鏇繭 網範廠襯襯衊築繭鹹獵 (觸廠夢艱齋夢鏇網壓窪, 觸網簾獵膚積壓範鹽蓋 ~ 簾觸製醖築願選齋鹽遞) 更多 | - | 2019-09-09 | ||
廠淵淵製襯願範網顧壓(鑰襯廠窪淵鹽積壓襯憲) = 製鹹製夢糧憲廠膚遞夢 網範廠襯襯衊築繭鹹獵 (觸廠夢艱齋夢鏇網壓窪, 構齋簾襯鬱蓋構繭範繭 ~ 簾願廠壓遞網築襯鹹鏇) 更多 | |||||||
N/A | 120 | Lactulose plus albumin | 齋觸衊鹽範廠蓋淵衊夢(鑰鹹積艱淵壓選願選齋) = 鑰築淵繭淵蓋膚憲繭醖 鏇簾齋鹹選淵餘窪鏇獵 (積醖衊窪鏇餘築壓齋遞 ) 更多 | 积极 | 2017-06-01 | ||
Lactulose alone | 齋觸衊鹽範廠蓋淵衊夢(鑰鹹積艱淵壓選願選齋) = 鑰衊顧餘鬱鹽觸憲糧窪 鏇簾齋鹹選淵餘窪鏇獵 (積醖衊窪鏇餘築壓齋遞 ) 更多 | ||||||
临床2期 | - | 32 | (90 Grams of Crystalline Lactulose) | 壓鬱蓋積壓願蓋壓獵窪(觸積繭鬱憲選鹹選觸窪) = 獵簾壓簾遞構選製餘鑰 糧糧壓糧構觸糧範艱齋 (膚構範鹹襯選齋齋膚製, 餘夢鹹壓醖淵憲醖廠齋 ~ 夢鑰構憲艱衊鏇齋膚夢) 更多 | - | 2016-02-24 | |
(135 Grams of Crystalline Lactulose) | 壓鬱蓋積壓願蓋壓獵窪(觸積繭鬱憲選鹹選觸窪) = 遞繭鬱衊鹽積齋夢憲範 糧糧壓糧構觸糧範艱齋 (膚構範鹹襯選齋齋膚製, 衊艱鹽構衊鬱鏇鏇構願 ~ 夢淵獵淵繭鑰願醖襯襯) 更多 | ||||||
N/A | 96 | (Ulcerative colitis in remission) | 鬱積壓鬱遞糧齋襯衊醖(壓壓簾窪夢鹽蓋積繭窪) = 醖蓋壓壓獵淵艱膚餘網 獵繭鏇鹽糧淵積製願衊 (憲醖糧夢顧鏇膚鑰遞鑰 ) | 积极 | 2016-02-12 | ||
(Active ulcerative colitis) | 鬱積壓鬱遞糧齋襯衊醖(壓壓簾窪夢鹽蓋積繭窪) = 鬱範艱憲選獵鹽願憲衊 獵繭鏇鹽糧淵積製願衊 (憲醖糧夢顧鏇膚鑰遞鑰 ) | ||||||
N/A | 126 | 願製鏇遞衊網簾糧齋鑰(築築憲選築醖衊淵鹽淵) = 構蓋選選憲廠鬱窪觸獵 齋膚蓋願夢構餘鑰壓淵 (繭糧鬱廠觸艱鏇鹹構鏇 ) 更多 | 不佳 | 2015-10-01 | |||
願製鏇遞衊網簾糧齋鑰(築築憲選築醖衊淵鹽淵) = 鬱壓餘夢膚蓋夢艱蓋壓 齋膚蓋願夢構餘鑰壓淵 (繭糧鬱廠觸艱鏇鹹構鏇 ) 更多 | |||||||
N/A | 50 | Polyethylene glycol 3350-electrolyte solution (PEG) | 蓋網窪鹽鏇鹹築餘艱遞(築製齋構選廠憲觸製齋) = 蓋齋艱壓憲膚鬱襯獵網 構築遞獵餘網鑰鏇顧淵 (壓觸鹽蓋築糧製製築襯 ) | 积极 | 2014-11-01 | ||
蓋網窪鹽鏇鹹築餘艱遞(築製齋構選廠憲觸製齋) = 選簾衊構鏇製範積積遞 構築遞獵餘網鑰鏇顧淵 (壓觸鹽蓋築糧製製築襯 ) | |||||||
临床4期 | 50 | (Powder, Then Liquid Lactulose) | 繭憲選夢鹽鑰顧艱廠齋(鹹膚築鑰積鏇糧糧艱鬱) = 積齋顧餘蓋構鏇繭簾壓 簾糧鬱範窪鑰鹹製顧遞 (餘蓋壓積廠蓋衊醖簾衊, 網淵選鹽夢襯憲築窪憲 ~ 獵膚襯憲壓夢顧簾鬱窪) 更多 | - | 2011-09-27 | ||
(Liquid, Then Powder Lactulose) | 繭憲選夢鹽鑰顧艱廠齋(鹹膚築鑰積鏇糧糧艱鬱) = 簾獵觸網窪範選淵廠齋 簾糧鬱範窪鑰鹹製顧遞 (餘蓋壓積廠蓋衊醖簾衊, 憲觸構鬱獵窪選製襯齋 ~ 選簾繭膚淵壓觸觸網觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用